Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04264208 · ClinicalTrials.gov registry record · Phase 2
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
A Phase 2 study, sponsored by Andrei Iagaru.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04264208 is a Phase 2 study that was terminated before completion, run by Andrei Iagaru. The registered enrollment target is 4 participants.
The verdict
NCT04264208, a Phase 2 study, was terminated before completion, sponsored by Andrei Iagaru.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)
Interventions
- DEVICE PET/MRI
- DRUG 68-Ga PSMA11
- DRUG 68-Ga RM2.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04264208
The ClinicalTrials.gov registry entry for NCT04264208 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PET/MRI is the first listed.
NCT04264208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04264208 about?
NCT04264208 is a clinical study titled "HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer". This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)
What is the current status of trial NCT04264208?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2020-02-05. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT04264208?
The interventions under investigation include: PET/MRI (DEVICE), 68-Ga PSMA11 (DRUG), 68-Ga RM2. (DRUG).
Who is sponsoring clinical trial NCT04264208?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.